Index

Note: Page numbers of article titles are in **boldface** type.

A

ABCDE mnemonic, for secondary hypertension, 528–529
Absorptive undergarments, for urinary incontinence, 549
ACCOMPLISH (Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension), 532
ACCORD study, for diabetes mellitus, 623
Acne, in testosterone replacement, 518
α-Adrenergic antagonists, for urinary incontinence, 548–549
ADVANCE study, for diabetes mellitus, 623
Aggressive behavior, in nursing homes, 603–605
Aging Male Symptoms Scale, 508–509
Agitation, in nursing homes, 603–605
Alfuzosin, for urinary incontinence, 548
ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), 532–534
Alzheimer’s disease, prevention of. See Brain, revitalization of.
American College of Sport and Medicine, physical activity recommendations of, 431
American Geriatrics Society, physical activity recommendations of, 431
American Heart Association, physical activity recommendations of, 431
Amino acids, for sarcopenia, 428–430
Amisulpride, for delirium, 569
Androgen Deficiency in Aging Male questionnaire, 508–509
Androgens
  deficiency of. See Hypogonadism.
  for osteoporosis, 499
Anemia, testosterone replacement effects on, 516
Anesthesia, delirium in, 556
Angiotensin receptor blockers
  for heart failure, 457
  for hypertension, 532–533
Angiotensin-converting enzyme inhibitors
  for heart failure, 457
  for hypertension, 532–533
  for sarcopenia, 432
  urinary incontinence due to, 542
Anorexia, 582
  in nursing homes, 599
  in sarcopenia, 428
Anthocyanins, in black rice, 484
Anthropometric values, 478–479
Anticholinergics
   for urinary incontinence, 547–548
   urinary incontinence due to, 542
Antidepressants, delirium due to, 560–561
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 532–534
Antimuscarinic drugs, for urinary incontinence, 547–548
Antipsychotics, for delirium, 566–570
Anxiety, cognitive impairment in, 466
Aphasia, in nursing homes, 601
Apnea, sleep
   testosterone replacement and, 518
   urinary incontinence in, 541
Appetite, reduction of, 428, 582, 584–585
Aripiprazole, for delirium, 569
Atenolol, for hypertension, 533
Atorvastatin, for dyslipidemia, 626
Attentiveness, for brain revitalization, 470–471
Avoiding Cardiovascular events through COmbination therapy in Patients Lliving
   with Systolic Hypertension (ACCOMPLISH), 532
Azoospermia, in testosterone replacement, 518

B
Bariatric surgery, for obesity, 588
Behavioral symptoms, in nursing homes, 603–605
Behavioral treatment, for urinary incontinence, 540, 542–543, 546–547
Benign prostatic hyperplasia, in testosterone replacement, 516–517
Bereavement, anorexia in, 584
Beta blockers, for hypertension, 532–534
Bisoprolol, for heart failure, 457
Bisphosphonates, for osteoporosis, 500, 502–503
Black rice, for healthy diet, 484
Black tea, for healthy diet, 484
Bladder diary, for incontinence, 542, 546
Bladder training, for incontinence, 542
Blood pressure, high. See Hypertension.
Body composition, 477–479
   testosterone replacement effects on, 513
   weight loss and, 580
Body mass index
   changes in, 577–578
   nutrition and, 477–479
Body weight. See Weight.
Bone mass density. See also Osteoporosis.
   in hypogonadism, 512–513
Botulinum toxin, for incontinence, 550
Brain, revitalization of, 463–475
   assessment for, 465–467
   cognitive strategies for, 469–471
   lifestyle modifications for, 467–469
neuroplasticity and, 463–465
patient handout for, 467
realistic expectations for, 471–472
risk factor reduction for, 466
steps for, 465–471
Brain exercises, for brain revitalization, 470–471
Brain natriuretic peptide, 451–452
Breath-awareness exercises, for brain revitalization, 468

C
Cachexia, 585, 599–600
Caffeine, urinary incontinence due to, 541
Calcitonin, for osteoporosis, 500
Calcium
dietary, 480
for osteoporosis, 500
Calcium channel blockers, for hypertension, 532–534
Calories, intake of, 479
Candesartan, for heart failure, 457
Carbohydrates
  disordered metabolism of. See Diabetes mellitus.
glycemic index of, 482
Cardiac resynchronization therapy, for heart failure, 457
Cardiomegaly, in heart failure, 443
Cardiovascular disease, in diabetes mellitus, 622
Cardiovascular Health Study, of weight loss, 580–581
Cardiovascular risk factors
cognitive impairment and, 455
testosterone replacement effects on, 515–516
CARDS (Collaborative Atorvastatin Diabetes Study), 626
CARE (Cholesterol and Recurrent Events), 626
Carvedilol, for heart failure, 457
Chinese diet, components of, 484–485
Chlorthalidone, for hypertension, 532–533
Cholestasis, in testosterone replacement, 517–518
Cholesterol and Recurrent Events (CARE), 626
Chronic heart failure. See Heart failure.
Cognitive and Emotional Health Project, 463
Cognitive function
  impaired
    after delirium, 557
    urinary incontinence with, 550
  improvement of. See Brain, revitalization of.
testosterone replacement effects on, 514–515
Cognitive reserve, 464
Collaborative Atorvastatin Diabetes Study (CARDS), 626
Communication, in nursing home care, 600–601, 606–607
Condom catheters, for urinary incontinence, 547, 549
Consciousness, altered level of, in delirium, 559
Constipation, urinary incontinence in, 541
Continuous quality improvement, for nursing home care, 595–599
Corticosteroids, brain revitalization and, 465
Creatine, for sarcopenia, 432
Creative activities, for brain revitalization, 471
Cunningham clamp, for urinary incontinence, 549
Cytokines, in anorexia, 584

D
Darifenacin, for urinary incontinence, 548
DASH diet, for hypertension, 530–531
DEFEAT-HF mnemonic, for heart failure, 440
Defibrillator, for heart failure, 457–458
Delirium, 555–577
  causes of, 560–563
  consequences of, 557
  definition of, 555
  evaluation of, 558–563
  historical view of, 555
  pathophysiology of, 555–556
  prevalence of, 556–557
  prevention of, 563–565
  subacute, 559
  subtypes of, 555
  treatment of, 563–571
    based on causes, 560–563
    nonpharmacologic, 570–571
    pharmacologic, 566–570
    physical restraints, 566
    versus dementia, 559–560
D-E-L-I-R-I-U-M mnemonic, 560–561
Dementia
  anorexia in, 585
  in nursing homes, 603–605
  urinary incontinence with, 550
  versus delirium, 559–560
Dentition, problems with, anorexia in, 585
Depression
  anorexia in, 584
  cognitive impairment in, 466
  delirium in, 561–562
  in diabetes mellitus, 602
  in hypogonadism, 508
  in nursing homes, 603–605
  osteoporosis in, 498–499
  testosterone replacement effects on, 514
Diabetes Control and Complications Trial, 620
Diabetes mellitus, 615–629
  cognitive impairment in, 466
  diagnosis of, 618–620
  epidemiology of, 615–617
Index

ethnic factors in, 616
in nursing homes, 602
management of, 623–627
pathophysiology of, 616, 618
testosterone replacement effects on, 515–516
types of, 616
urinary incontinence in, 541
vascular complications of, 620, 622–623
Diary, for urinary incontinence, 542, 546
Dietary quality index, 484–485
Digoxin, for heart failure, 456–457
Dipeptidyl-peptidase-IV inhibitors, for diabetes mellitus, 624
Diuretics
for heart failure, 456–457
for hypertension, 532–533
urinary incontinence due to, 541
Dopaminergic system, imbalance of, in delirium, 555–556
Doxazosin
for hypertension, 533
for urinary incontinence, 549
Drugs. See also specific drugs.
anorexia due to, 582, 585
cognitive impairment due to, 466
delirium due to, 560–561
hip fractures due to, 501–502
osteoporosis due to, 499
polypharmacy with, in nursing homes, 599
urinary incontinence due to, 541–542
weight loss due to, 599
Duloxetine, for urinary incontinence, 547–548
Dutasteride, for urinary incontinence, 549
Dyslipidemia
in diabetes mellitus, 625–627
in metabolic syndrome, 621
Dysphasia, in nursing homes, 601
Dyspnea, in heart failure, 442, 449–452

E
Economic status, nutrition and, 485–486
Ejection fraction, in heart failure, 453
Electrolyte imbalance, cognitive impairment in, 466
Emotional state, delirium due to, 561–562
Endurance training, for sarcopenia, 431
Eplerenone, for heart failure, 457
Erectile dysfunction, in hypogonadism, 508, 512
Erythrocytosis, in testosterone replacement, 518
Estrogen
for osteoporosis, 500
for urinary incontinence, 547–548
European Diabetes Working Party for Older People, 624
European Working Party on High Blood Pressure in the Elderly (EWPHE), 528, 532–533

Executive function, improvement of, 468–469

Exenatide, for diabetes mellitus, 624

Exercise
  for brain revitalization, 468–469
  for diabetes mellitus, 623
  for hypertension, 530–531
  for obesity, 588
  for sarcopenia, 430–431
  for urinary incontinence, 542–543
  in nursing homes, 599

Exetimibe, for dyslipidemia, 625

Eye disease, diabetic, 620

F

Falls, 495–497, 602–603

Fat, dietary, 479–480

Fatigue
  in frailty, 427–428
  in heart failure, 442, 449–452
  testosterone replacement effects on, 513–514

Fatty acids, dietary, 481

Fecal retention, delirium due to, 562

Finasteride for urinary incontinence, 549

Fish oil, for hypertension, 531

Fluid volume status, in heart failure, 446–447, 452–455

Follicle-stimulating hormone, in hypogonadism, 509

Foot, diabetic, 622

Forgetfulness, prevention of. See Brain, revitalization of.

Fractures
  hip, 500–504, 603
  in nursing homes, 603
  in osteoporosis, 497–498

Frailty, 427–438
  causes of, 428
  definition of, 427
  nutrition for, 428–430
  pharmacotherapy for, 431–432
  physical activity for, 430–431
  symptoms of, 427–428
  testosterone replacement effects on, 513

Framingham Heart Study, hypertension results of, 527–528

Framingham Osteoporosis Study, 498

Fruits, for healthy diet, 482

Functional foods, 482–484

Furosemide, for heart failure, 456–457

G

Games, for brain revitalization, 470–471

Garlic, for hypertension, 531
Gastrointestinal disorders, anorexia in, 582
Geriatric medicine
  brain revitalization, 463–475
  delirium, 555–577
  diabetes mellitus. See Diabetes mellitus.
  falls, 495–497, 602–603
  frailty, 427–438, 513
  heart failure, 439–461, 516
  hip fracture, 500–504, 603, 606
  hypertension. See Hypertension.
  hypogonadism, 507–523
  incontinence, 539–554, 605–606
  insulin resistance, 615–629
  nursing home care, 556–557, 595–614
  nutrition. See Nutrition.
  osteoporosis, 497–500, 508, 512–513
  sarcopenia, 427–438
  weight loss, 579–593
Ghrelin, for sarcopenia, 432
Gliclazide, for diabetes mellitus, 624
Glimepiride, for diabetes mellitus, 624
Glitpints, for diabetes mellitus, 624
Glucose control, for diabetes mellitus, 623–624
Glucose metabolism, disorders of. See Diabetes mellitus.
Glycemic control, for diabetes mellitus, 623–624
Glycemic index, of foods, 482
Green tea, for healthy diet, 483–484
Growth hormone, for sarcopenia, 432
Gynecomastia, in testosterone replacement, 518

H
Hallucinations
  in delirium, 570
  in nursing homes, 603–605
Haloperidol, for delirium, 567–568, 570
Health, Aging and Body Composition study, of nutrition, 429
Hearing deficit
  cognitive impairment int, 466
  in nursing homes, 600–601
Heart, aging physiology of, 525–527
Heart failure, 439–461
  case presentations of, 440–449
  cognitive impairment in, 466
  diagnosis of, 439–440, 442–444, 449–452
  ejection fraction in, 453
  epidemiology of, 439
  etiology of, 445, 452
  fluid volume status in, 446–447, 452–455
  risk factors for, 452
  symptoms of, 442–444
Heart failure (continued)
  testosterone replacement effects on, 516
  treatment of, 453, 456–458
Heart Protection Study (HPS), 626
Helsinki Ageing Study, 528
Hepatogenous reflux, in heart failure, 453
Hepatotoxicity, of testosterone replacement, 517–518
Hip fractures, 500–504, 603
Hip protection devices, 502
Home care, delirium in, 557
Homocysteine, elevated, in osteoporosis, 498
Hormonal deficiency, cognitive impairment in, 466
HPS (Heart Protection Study), 626
Hydrochlorothiazide, for hypertension, 532–533
Hypertension, 525–537
  aging physiology and, 525–527
  classification of, 527–528
  cognitive impairment in, 466
  dietary factors in, 480
  heart failure in, 445
  in diabetes mellitus, 624–625
  in metabolic syndrome, 621
  orthostatic hypotension and, 530
  secondary, 528–530
  treatment of, 624–625
    goals of, 527–528
    nonpharmacologic, 530–531
    pharmacologic, 531–534
Hypertension in the Very Elderly Trial (HYVET), 532–533
Hypertriglyceridemia, cognitive impairment in, 466
Hypnotics, urinary incontinence due to, 542
Hypoglycemia
  in diabetes mellitus treatment, 624
  response to, 616, 618
Hypogonadism, 507–523
  diagnosis of, 508–509
  incidence of, 507
  risk factors for, 509
  symptoms of, 507–509
  testosterone levels in, 507–508
  treatment of, 510–520
    anemia and, 516
    benefits of, 511–516
    cardiovascular risk factors and, 515–516
    delivery systems for, 510–511
    metabolic syndrome and, 515–516
    monitoring of, 519
    precautions with, 519–520
    risks of, 516–518
    symptom relief in, 518
Hypotension, orthostatic, 530
Hypoxia, delirium due to, 562
HYVET (Hypertension in the Very Elderly Trial), 532–533

I
Immobility, anorexia in, 585
Implantable cardioverter with defibrillator, for heart failure, 458
Incontinence, urinary. See Urinary incontinence.
Indapamide, for hypertension, 532–533
Infections, delirium in, 562
Insulin, for diabetes mellitus, 624
Insulin resistance, 616, 618, 620–621
Intensive care unit, delirium in, 556–557
Interdependence, in nursing home care, 606
Internal jugular vein myth, in heart failure, 452–453
International Diabetes Federation, metabolic syndrome definition of, 621
International Prostate Symptom Score, 519
International Verapamil SR/Trandolapril (INVEST) study, 528
Isoflavones, in soy foods, 482–483

J
Jugular venous pressure, in heart failure, 451–455
Justification for the Use of statins in prevention: an intervention Trial Evaluating Rosuvastatin (JUPITER), 626

K
Kegel exercises, for urinary incontinence, 542–543
Kidney disease, diabetic, 622

L
Learning
  for brain revitalization, 470
  neuroplasticity and, 464–465
Leucine, for sarcopenia, 430
Libido, decreased, in hypogonadism, 507, 512
Lifestyle modification
  for brain revitalization, 467–469
  for diabetes mellitus, 623
  for hypertension, 530–531
  for obesity, 588
Linoleic acid, for hypertension, 531
LIPID (Long-term Intervention with Pravastatin in Ischemic Disease), 626
Lipoproteins
  elevated, in diabetes mellitus, 625–627
  testosterone replacement effects on, 515–516
Liraglutide, for diabetes mellitus, 624
Liver disorders, testosterone replacement effects on, 517–518
Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), 626
Luteinizing hormone, in hypogonadism, 509
Macronutrients, 479–480
Magnesium, dietary, 480
Malnutrition, cognitive impairment in, 466
MEALS-ON-WHEELS mnemonic, 428, 600
Meaningful activity, in nursing homes, 599
Medications. See Drugs.
Mediterranean diet
components of, 484–485
for brain revitalization, 469
Memory
improvement of. See Brain, revitalization of.
testosterone replacement effects on, 514–515
Metabolic syndrome, 515–516, 616, 618, 620–621
Metformin, for diabetes mellitus, 602, 624
Metoprolol, for heart failure, 457
Mianserin, for delirium, 567
Microalbuminuria
in diabetes mellitus, 622
in metabolic syndrome, 621
Micronutrients, 480–481
Mini Nutritional Assessment, 428, 599
Minimum Data Set collection, in nursing homes, 596–598
Mixed incontinence, 539
Mobility impairment, urinary incontinence in, 541
Mobility Interaction Fall Chart, 496–497
Mood, testosterone replacement effects on, 513–514
Multiple Risk Factor Intervention Trial, hypertension results of, 527–528
Muscle(s)
loss of. See Sarcopenia.
testosterone replacement effects on, 513
Muscle relaxants, delirium due to, 561
Mushrooms, for healthy diet, 483
Myocardial infarction, in delirium, 562
Myostatin inhibitors, for sarcopenia, 432

N
Narcotics, delirium due to, 561
National Association for Continence, 542, 549
National Cholesterol Education Program, metabolic syndrome definition of, 621
National Diabetes Data Group, 618
Nephropathy, diabetic, 622
Neuropathy, diabetic, 622
Neuroplasticity, 463–465
Neurotransmitters, imbalance of, in delirium, 555–556
Nursing home care, 595–614
behavioral symptoms in, 603–605
communication in, 600–601, 606–607
delirium in, 556–557
dementia in, 603–605
diabetes mellitus in, 602
fall prevention in, 602–603
hearing loss problems in, 600–601
meaningful activity in, 599
oral health care in, 601
polypharmacy monitoring in, 599
population statistics and, 595
pressure ulcers in, 601
quality improvement in, 595–599
relational aspects of, 606
truth telling in, 606–607
urinary incontinence in, 605–606
weight loss in, 599–600

Nutrition, 477–493
  dietary patterns in, 484–485
  food categories in, 482
  for brain revitalization, 469
  for diabetes mellitus, 623
  for frailty, 428–430
  for hypertension, 530–531
  for obesity, 588
  for sarcopenia, 428–430
  functional foods in, 482–484
  in nursing homes, 599–600
  key nutrients in, 479–481
  optimal body weight and, 477–479
  social factors in, 485–486

O

Obesity, 478–479
  diabetes mellitus and, 616
  metabolic syndrome and, 621
  urinary incontinence in, 541
  weight loss for, 585–588
Olanzapine, for delirium, 567–570
Omega-3 fatty acids, 481
Onusko ABCDE mnemonic, for secondary hypertension, 528–529
Oral health, in nursing homes, 601
Orientation questions, in delirium, 559
Orthopnea, in heart failure, 442, 449–452
Orthostatic hypotension, 530
Osler maneuver, for hypertension evaluation, 529
Osteoporosis, 497–500
  hip fractures in, 500–504
  in hypogonadism, 508, 512–513
Overnutrition, 478–479
Overweight, 585–588
Oxford diabetes community study, 616
Pacemaker, for heart failure, 457–458

Pain
  - cognitive impairment in, 466
  - delirium in, 562–563
  - neuropathic, in diabetes mellitus, 622

Parkinson disease, osteoporosis in, 497–498

Pelvic floor exercises, for urinary incontinence, 542–543

Penile devices, for urinary incontinence, 547, 549

Performance Oriented Mobility Assessment, 496–497

Peripheral neuropathy, diabetic, 622

Perisperone, for delirium, 569

Pessaries, for urinary incontinence, 547

Physical activity. See Exercise.

Physical restraints, for delirium, 566

Phytoestrogens, dietary, 482–483

Pioglitazone, for diabetes mellitus, 624

Polypharmacy, in nursing homes, 599

Postprandial hypotension, 530, 603

Postural hypotension, 530

Postvoid residual volume, in urinary incontinence, 540

Potassium
  - dietary, 480
    - for hypokalemia, 456–457

Practice, for grain revitalization, 464–465

Pravastatin, for dyslipidemia, 626

Prazosin, for urinary incontinence, 549

Pressure ulcers, 601

Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), 626

Prostate, testosterone replacement effects on, 516–517, 519–520

Protein(s)
  - dietary, 479
    - for sarcopenia, 428–430

Protein-energy malnutrition, 583

Pseudohypertension, 529

Psychological factors, in anorexia, 582

Q

Quality improvement, for nursing home care, 595–599

Quality of life, testosterone replacement effects on, 513–514

Quetiapine, for delirium, 567–569

R

Raloxifen, for osteoporosis, 500

5α-Reductase inhibitors, for urinary incontinence, 547–549

Relationships, in nursing home care, 606

Relaxation, for brain revitalization, 468

Reserpine, for hypertension, 533
Resistance training, for sarcopenia, 430–431
Restraints, for delirium, 566
Retinopathy, diabetic, 620
Rice, black, for healthy diet, 484
Risedronate, after hip fracture, 502
Risperidone, for delirium, 570, 587
Rosuvastatin, for dyslipidemia, 626

Sacral neuromodulation, for incontinence, 550
Salt, dietary, 480
Sarcopenia, 427–438, 580
  causes of, 428
  definition of, 428
  nutrition for, 428–430
  pharmacotherapy for, 431–432
  physical activity for, 430–431
  symptoms of, 427–428
  testosterone replacement effects on, 513
Scandinavian Simvastatin Survival Study, 626
Scottish Hip Fracture Audit database, 503
Screening, for delirium, 558–560
Sedatives, urinary incontinence due to, 542
Seizures, delirium in, 563
Selective androgen receptor modulators, for sarcopenia, 432
SHEP (Systolic Hypertension in the Elderly Program), 532–533, 581
Silodosin, for urinary incontinence, 549
Simon Foundation, incontinence information from, 542
Simplified Nutrition Assessment Questionnaire, 428, 599
Simvastatin, for dyslipidemia, 626
Sleep apnea
  testosterone replacement and, 518
  urinary incontinence in, 541
Sleep disorders, cognitive impairment in, 466
SLEEP N Pills handout, for brain revitalization, 467
Social factors
  in anorexia, 582, 584–585
  in nutrition, 485–486
Socially active lifestyle, for brain revitalization, 469
Sodium
  dietary, 480
  reduction of, for hypertension, 530–531
Solifenacin, for urinary incontinence, 548
Soy foods, 482–483
Spironolactone, for heart failure, 456–457
Statins, for dyslipidemia, 625–627
STOP-HTN 2 (Swedish Trial in Old Patients with Hypertension-2 Study), 532–533
Strength
  loss of, in frailty, 427–428
  resistance training for, 430–431
Strength (continued)
  testosterone replacement effects on, 513
Stress
  aging as, 584
  neurotoxicity of, 465
  reduction of, for brain revitalization, 467–468
Stress incontinence, 539
Stroke
  anorexia in, 585
  delirium in, 562
Subdural hematoma, delirium in, 563
Substance abuse, cognitive impairment due to, 466–467
Sulfonylureas, for diabetes mellitus, 624
Surgery
  delirium in, 556
  for obesity, 588
Swedish Trial in Old Patients with Hypertension-2 Study (STOP-HTN 2), 532–533
Swelling, in heart failure, 442, 449–452
Synthetic androgen modulators, for sarcopenia, 432
Systolic Hypertension in the Elderly Program (SHEP), 532–533, 581

T
TADA approach, to delirium, 570–571
Tamulosin, for urinary incontinence, 549
Tea, for healthy diet, 483–484
Terazosin, for urinary incontinence, 549
Testosterone
  deficiency of. See Hypogonadism.
  for sarcopenia, 431–432
  measurement of, 509
Thiazide diuretics, for hypertension, 532–533
Tibolone, for sarcopenia, 432
Timed Up and Go test, 496–497
Tinetti Balance and Gait Assessment tool, 496–497
Tolterodine, for urinary incontinence, 548
TONE (Trial of Nonpharmacologic Interventions in the Elderly), 530–531
Tooth brushing, 601
Torsemide, for heart failure, 456–457
Trial of Nonpharmacologic Interventions in the Elderly (TONE), 530–531
Triamterene, for hypertension, 533
Trospium, for urinary incontinence, 548
Truth telling, in nursing home care, 606–607

U
Ulcers
  diabetic, 622
  pressure, 601
Undergarments, absorptive, for urinary incontinence, 549
Undernutrition, 477, 583–585
United Kingdom Prospective Diabetes Study, 620
Urethral slings, for incontinence, 549–550
Urge incontinence, 539
Urinalysis, for urinary incontinence, 540
Urinary incontinence, 539–554
    epidemiology of, 539–540
    evaluation of, 540–541
    impact of, 539–540
    in nursing homes, 605–606
    treatment of, 540–551, 605–606
        algorithm for, 540, 544–545
        behavioral, 540, 542–543, 546–547
        devices for, 547, 549
        pharmacologic, 547–549
        referral for, 551
        surgical, 549–550
        with cognitive impairment, 550
Urinary tract infections, 540–541
Urine, retention of, delirium due to, 562

V
Vascular system
    aging physiology of, 525–527
    diabetes mellitus effects on, 620, 622–627
Vegetables, for healthy diet, 482
Vegetarian diet, 485
Vildagliptin, for diabetes mellitus, 624
Vision deficit, cognitive impairment in, 466
Vitamin(s), 480–481
Vitamin D
    for osteoporosis, 500, 502
    for sarcopenia, 430
    requirements for, 481

W
Walking tests, 496–497
Weight, optimal/ideal, 477–479, 581, 583
Weight loss, 579–593
    body composition and, 580
    causes of, 583–585
    consequences of, 580–583
    for obesity, 585–588
    for urinary incontinence, 546
    ideal body weight and, 581, 583
    in frailty, 427–428
    in nursing homes, 599–600
    muscle. See Sarcopenia.
    pathologic, 584–585
    physiology of, 579–580, 584
Weight loss (continued)
undernutrition and, 583
West of Scotland Coronary Prevention Study, 626
World Health Organization, metabolic syndrome definition of, 620–621

Z
Zoledronic acid, after hip fracture, 503